Researchers track Long-Term effects of romiplostim in rare blood disorder
NCT ID NCT04870346
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study follows 36 patients with aplastic anemia who previously received romiplostim in earlier trials. Researchers will monitor blood cell counts and safety for up to 5 years to see if benefits last and to check for any new health issues. The goal is to better understand the long-term effects of this treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
romiplostim
What this could lead to
If successful, this could confirm whether romiplostim provides lasting benefits for aplastic anemia patients without ongoing treatment.
What could go wrong
This is an observational follow-up, not a new treatment trial. It may not show clear long-term benefits, and results depend on a small group of patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kanazawa University, College of Medical Pharmaceutical and Health Sciences, School of Medicine, Department of Hematology
Kanazawa, Ishikawa-ken, 920-0934, Japan